StockWatch
·
HomeLiveWeekly
Biotechnology: Biological Products (No Diagnostic Substances)
Business UpdateJul 7, 2026, 07:06 AM

OKYO Pharma to participate in Piper Sandler Ophthalmology Symposium

AI Summary

OKYO Pharma Limited announced its participation in the Piper Sandler Virtual Ophthalmology Symposium, scheduled for July 9, 2026. CEO Robert J. Dempsey and Chief Medical Officer Flavio Mantelli MD, PhD, will present during a fireside chat at 8:30 AM ET. The virtual event will be moderated by Biren Amin from Piper Sandler & Co.

Key Highlights

  • OKYO Pharma will participate in the Piper Sandler Virtual Ophthalmology Symposium.
  • The event is scheduled for Thursday, July 9, 2026, at 8:30 AM ET.
  • Presenters include CEO Robert J. Dempsey and CMO Flavio Mantelli MD, PhD.
  • The fireside chat will be moderated by Biren Amin from Piper Sandler & Co.
View SEC Filing
OKYO
Biotechnology: Biological Products (No Diagnostic Substances)
OKYO Pharma Ltd

Price Impact

More from OKYO

USFDA11h ago

OKYO Pharma Gets Positive FDA Feedback for Urcosimod Phase 3 Trial

USFDA11h ago

OKYO Pharma gets FDA alignment for single-trial Phase 3 urcosimod

Management ChangeMay 19, 7:02 AM

OKYO Pharma Expands Scientific Advisory Board with Dr. Marta Sacchetti

More in Business Update

NOA1h ago

NACG Awarded Five-Year, $135M Heavy Equipment Services Contract

NOA1h ago

North American Construction Group Subsidiary Wins $135M Contract

SR1h ago

Spire Recasts FY25 Financials; Discontinued Ops & Segment Changes